Hepatitis C Challenge: Caring Ambassadors Hep C Program
 HepC Choices

Hepatitis News:

June 2006

Caring Ambassadors Program Offering Free Hepatitis C Counseling and Screening at Portland Waterfront Blues Festival
"OREGON CITY, OR -- June 21, 2006 -- Free, confidential hepatitis C counseling and screening will be provided by the Caring Ambassadors Hepatitis C Program (CAP-Hepatitis C) at the upcoming Portland Waterfront Blues Festival. CAP-Hepatitis C staff and volunteers will be available in the Good Neighbor Pharmacy Health Pavilion throughout the festival hours of operation. The festival takes place from June 30th through July 4th at Tom McCall Waterfront Park."

Study Suggests Caffeine Can Help Liver
"Coffee and tea may reduce the risk of serious liver damage in people who drink too much alcohol, are overweight or have too much iron in the blood, researchers reported yesterday."

Hepatitis C Vaccine Looks Promising: Disease Effects Four Million Americans
"A new vaccine could save millions of people from developing a deadly disease. Doctors says there soon may be a way to prevent hepatitis C, early clinical trials look extremely promising."

Study shows hepatitis C may be the cancer culprit
"A new study conducted in Taiwan suggests that the hepatitis C virus is the true culprit behind the nation's rising rates of hepatocellular carcinoma (a common type of liver cancer), debunking theories that the hepatitis B virus was mostly to blame."

Coming Together to Fight Hep C in California
"A policy meeting in Sacramento last month brought together about 100 advocates, including representatives of the Drug Policy Alliance, to discuss California's hepatitis C epidemic and form a statewide policy coalition."

Peregrine's hepatitis C trial shows promise
"Peregrine Pharmaceuticals Inc. reported Wednesday that an early-stage clinical trial showed the biotech drug developer's hepatitis C treatment lowered concentrations of the virus in patients after one dose. "

Novartis, Human Genome Sciences to co-market hepatitis C drug Albuferon
"Novartis AG said it has signed an exclusive worldwide agreement with US biopharmaceuticals company Human Genome Sciences to acquire rights to hepatitis C drug Albuferon. The investigational drug is expected to enter Phase III clinical trials by the end of 2006, Novartis said."

Vertex partners with J&J for hepatitis C drug
"Vertex Pharmaceuticals said Friday that it has partnered with Johnson & Johnson for the commercialization of its hepatitis C drug candidate VX-950."

Nabi teams up with Italian firm for hepatitis C drug
"Nabi Biopharmaceuticals has secured an agreement with an Italian biopharmaceutical company for the co-development and possible commercialization of a treatment about to enter mid-stage testing for hepatitis C.
Under the deal, Nabi and Kedrion will pursue a strategy to develop and possibly get the drug, called Civacir, approved by health regulators in the United States and Europe."

Graphic hepatitis C ads raise ethical qualms
"As the head of liver transplantation at Thomas Jefferson University Hospital, Victor J. Navarro has seen many ailing patients with hepatitis C. But they don't look like the man in a half-page, color newspaper ad with a battered and bruised face, his eyes glassy. 'If Hep C was attacking your face instead of your liver, you'd do something about it,' the ad reads. 'Ready to fight back?'"

Overweight people have poor response to hepatitis C treatment
"New research suggests that obese patients in treatment for chronic hepatitis C infection are more likely to achieve better results if the abnormalities associated with excessive fat tissue are corrected first."

Cookbook profits to benefit hepatitis C research: Family collection is the backbone of expanded version
"Debbie Green decided something had to be done. A close relative of hers had been living for years with hepatitis C, a liver disease spread by the hepatitis C virus."

More than 700 patients of a former Gwynedd health care worker diagnosed with hepatitis C called a special hotline for advice on its first day.
"About 5,000 patients have been sent letters with the phone number, and 400 people have now booked blood tests for hepatitis C and B and HIV. Five of the 47 special clinics set up for blood testing were fully booked."

Huge numbers of Hep B and C cases here
"A huge increase in reported cases of Hepatitis B in Ireland over the past decade is due to better screening programmes and an increasing number of cases which have originated abroad and among IV drug users, according to the Health Protection Surveillance Centre (HPSC). It says there is also a very high incidence of hepatitis C in Ireland at present."

Local group to appeal for Hep C compensation in Ottawa
"The Sudbury Hepatitis C Support Group is heading to Ottawa in hopes of getting federal Health Minister Tony Clement to promise compensation for Hepatitis C victims who received tainted blood transfusions."

Commission: Asperilla should compose hepatitis C proposal: Outline needed before board grants money for treatment
"Dr. Mark Asperilla pleaded to Charlotte County commissioners Tuesday for money to help end what he and other local physicians claim is a hepatitis C epidemic in the county"

Largest U.S. Hepatitis C Trial Provides Insight Into Optimizing Treatment
"Researchers who participated in the WIN-R trial, the largest hepatitis C study ever conducted in U.S. patients, reported key factors affecting treatment outcomes in five data presentations at the Digestive Disease Week (DDW) annual meeting, and provided important insights for optimizing treatment with PEG-INTRON® (peginterferon alfa-2b) and REBETOL® (ribavirin, USP) combination therapy for patients with chronic hepatitis C virus (HCV) infection, a potentially deadly liver disease."
 

Clinical Trials, Cohort Studies, Pilot Studies

Sexual dysfunction is highly prevalent among men with chronic hepatitis C virus infection and negatively impacts health-related quality of life. Danoff A, et al. Am J Gastroenterol. 2006 Jun;101(6):1235-43.

Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease? Thabut D, et al. Am J Gastroenterol. 2006 Jun;101(6):1260-7.

A study of low dose peginterferon alpha-2b with ribavirin for the initial treatment of chronic hepatitis C.
Krawitt EL, et al. Am J Gastroenterol. 2006 Jun;101(6):1268-73.

HCV genotype 4 in Belgium: three distinct patterns among patients from European and African origin.
Delwaide J. et al. Eur J Gastroenterol Hepatol. 2006 Jul;18(7):707-712.

Long-Term Follow-Up of Previous Hepatitis C Virus Positive Nonresponders to Interferon Monotherapy Successfully Retreated with Combination Therapy: Are They Really Cured? Ciancio A, et al. Am J Gastroenterol. 2006 Jun 16; [Epub ahead of print].

Re-treatment of chronic hepatitis C patients after relapse: efficacy of peginterferon-alpha-2a (40 kDa) and ribavirin. Berg C, et al. J Viral Hepat. 2006 Jul;13(7):435-40.

Long-Term Follow-Up of Previous Hepatitis C Virus Positive Nonresponders to Interferon Monotherapy Successfully Retreated with Combination Therapy: Are They Really Cured? Ciancio A, et al. Am J Gastroenterol. 2006 Jun 16; [Epub ahead of print]

Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. Sherman M, et al. Gut. 2006 Jun 27; [Epub ahead of print]

More Advanced Hepatic Fibrosis in Hispanics with Chronic Hepatitis C Infection: Role of Patient Demographics, Hepatic Necroinflammation, and Steatosis. Verma S, et al. Am J Gastroenterol. 2006 Jun 22; [Epub ahead of print]

Risk factors for retinopathy associated with interferon alpha-2b and ribavirin combination therapy in patients with chronic hepatitis C. Okuse C, World J Gastroenterol. 2006 Jun 21;12(23):3756-9.

Pulmonary alterations in patients with chronic HCV infection. Erturk A, Dig Liver Dis. 2006 Jun 19; [Epub ahead of print]

[Early virologic response in retherapy with pegylated interferon alpha-2B plus ribavirin in children with chronic hepatitis C] [Article in Polish] Pawlowska M, Palewicz E, Halota W. Przegl Epidemiol. 2006;60(1):71-7.
 

Basic And Applied Science, Pre-Clinical Studies

Mutations in carboxy-terminal part of E2 including PKR/eIF2alpha phosphorylation homology domain and interferon sensitivity determining region of nonstructural 5A of hepatitis C virus 1b: Their correlation with response to interferon monotherapy and viral load. Ukai K, et al. World J Gastroenterol. 2006 Jun 21;12(23):3722-8.

Regulation of the CYP1A1 Gene by 2,3,7,8-Tetrachlorodibenzo-p-dioxin, but not {beta}-Naphthoflavone or 3-Methylcholanthrene, is Altered in Hepatitis C Virus Replicon-Expressing Cells. Anderson GR, Hasan A, Yin H, Qadri I, Quattrochi LC. Mol Pharmacol. 2006 Jun 20; [Epub ahead of print]

Behavioral and physiological effects of a single injection of rat interferon-alpha on male Sprague-Dawley rats: A long-term evaluation. Kentner AC, Miguelez M, James JS, Bielajew C. Brain Res. 2006 Jun 20;1095(1):96-106. Epub 2006 May 18.

Different anti-HCV profiles of statins and their potential for combination therapy with interferon.
Ikeda M, et al. Hepatology. 2006 Jul;44(1):117-25.

Outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviral memory CD8 responses. Urbani S, et al. Hepatology. 2006 Jul;44(1):126-39.

Increased hepatic expression of insulin-like growth factor-I receptor in chronic hepatitis C. Stefano JT, et al. World J Gastroenterol. 2006 Jun 28;12(24):3821-8.

Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans. Helle F, et al. J Biol Chem. 2006 Jun 29; [Epub ahead of print]
 

HIV/HCV Coinfection

Viral kinetics and early prediction of nonresponse to peg-IFN-alpha-2b plus ribavirin in HCV genotypes 1/4 according to HIV serostatus. Moreno A, et al. J Viral Hepat. 2006 Jul;13(7):466-73.

Hepatitis C Infection Is Associated with Depressive Symptoms in HIV-Infected Adults with Alcohol Problems. Libman H, et al. Am J Gastroenterol. 2006 Jun 16; [Epub ahead of print]

Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. McGovern BH, et al. Clin Infect Dis. 2006 Aug 1;43(3):365-72. Epub 2006 Jun 22.

National survey of HIV and hepatitis testing and vaccination services provided by drug and alcohol agencies in Australia. Winstock AR, Anderson CM, Sheridan J. Med J Aust. 2006 Jun 5;184(11):560-2.

Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection. Hornberger J, et al. J Clin Virol. 2006 Jun 7; [Epub ahead of print]

Gender differences in quality of HIV care in Ryan White CARE Act-funded clinics. Hirschhorn LR, et al. Womens Health Issues. 2006 May-Jun;16(3):104-12.

Complementary And Alternative Therapies

Effects on gene expression and viral load of a medicinal extract from Agaricus blazei in patients with chronic hepatitis C infection. Grinde B, Hetland G, Johnson E. Int Immunopharmacol. 2006 Aug;6(8):1311-4. Epub 2006 May 11.

Oxidative stress and antioxidant defense in patients with chronic hepatitis C patients before and after pegylated interferon alfa-2b plus ribavirin therapy. Gorenek L, et al. J Transl Med. 2006 Jun 20;4(1):25 [Epub ahead of print].

Miscellaneous Works

A statistical model predicting high hepatocyte proliferation index and the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Azzaroli F, et al. Aliment Pharmacol Ther. 2006 Jul 1;24(1):129-36.

Case finding for hepatitis C in primary care: a cost utility analysis. Coon JT, et al. Fam Pract. 2006 Jun 23; [Epub ahead of print]

Estimating the cost-effectiveness of detecting cases of chronic hepatitis C infection on reception into prison.
Sutton AJ, Edmunds WJ, Gill ON. BMC Public Health. 2006 Jun 27;6(1):170 [Epub ahead of print]

Rate of infectious complications during interferon-based therapy for hepatitis C is not related to neutropenia. Cooper CL, Al-Bedwawi S, Lee C, Garber G. Clin Infect Dis. 2006 Jun 15;42(12):1674-8. Epub 2006 May 10.

Organizational change in management of hepatitis C: Evaluation of a CME program. Garrard J, et al. J Contin Educ Health Prof. 2006 Spring;26(2):145-60.

 

Donate Now Give a gift in celebration
Give a gift in memory
Shop for Us

Hepatitis C is the most common, chronic blood-borne
viral infection in the U.S.